Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects

Abstract

Warfarin is used in paediatric populations, but dosing algorithms incorporating pharmacogenetic data have not been developed for children. Previous studies have produced estimates of the effect of polymorphisms in Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) on stable warfarin dosing, but data on time in therapeutic range, initial dosing and adverse effects are limited. Participants (n=97) were recruited, and routine clinical data and salivary DNA samples were collected from all participants and analysed for CYP2C9*2, *3 and VKORC1-1639 polymorphisms.VKORC1 -1639 was associated with a greater proportion of the first 6 months’ treatment time spent within the target International Normalised Ratio (INR) range, accounting for an additional 9.5% of the variance in the proportion of time. CYP2C9*2 was associated with a greater likelihood of INR values exceeding the target range during the initiation of treatment (odds ratio (OR; per additional copy) 4.18, 95% confidence interval (CI) 1.42, 12.34). CYP2C9*2 and VKORC1-1639 were associated with a lower dose requirement, and accounted for almost 12% of the variance in stable dose. VKORC1-1639 was associated with an increased likelihood of mild bleeding complications (OR (heterozygotes vs homozygotes) 4.53, 95% CI 1.59, 12.93). These data show novel associations between VKORC1-1639 and CYP2C9*2 and INR values in children taking warfarin, as well as replicating previous findings with regard to stable dose requirements. The development of pharmacogenomic dosing algorithms for children using warfarin has the potential to improve clinical care in this population.

Introduction

Warfarin, a synthetic coumarin used for anticoagulation, has a narrow therapeutic index and exhibits wide interindividual variation in the maintenance dose required (0.5 mg per day to 20 mg per day). Proportionally, far fewer children are treated with warfarin than adults. Indications for paediatric use include treatment of thromboembolic disorders, prophylaxis for heart valve replacement, following cavopulmonary shunts and completion of the Fontan circulation in patients with complex congenital heart disease.1 Warfarin requires regular therapeutic monitoring through the use of the International Normalised Ratio (INR). The INR required for successful anticoagulation varies by indication for anticoagulation (Supplementary Table 1), following national recommendations.2

The pharmacokinetics and pharmacodynamics of warfarin in the young differ both from adults,1, 3, 4 and across childhood.3, 5, 6 Within children, dose requirements have been shown to be affected by weight (directly associated), and age (inversely associated).3, 5, 6, 7 Drug interactions also contribute to dose variation.5

Polymorphisms in two genes, vitamin K epoxide reductase complex subunit 1 (VKORC1) and Cytochrome P450 2C9 (CYP2C9), in combination with environmental factors, have a significant effect on warfarin dosing in adults.8, 9, 10 Adult patients from a variety of ethnic backgrounds with the variant allele(s) in one of the recognised polymorphisms in the VKORC1 gene (rs9923231, VKORC1-1639), and/or a variant allele(s) in polymorphisms in the CYP2C9 gene (rs1057910 and rs1799853, CYP2C9*2 and *3, respectively) require lower doses of warfarin.9, 11, 12, 13, 14, 15, 16, 17, 18 In adults, up to 30% of the dose variation can be explained by these two genetic factors,19 increasing to between 31.4 and 58.7% when clinical factors (including age, sex, drug interactions, ethnicity, body mass index and so on) are incorporated.19 Dosing algorithms that incorporate this pharmacogenetic data have been developed for adult patients9, 20 and shown to be more effective than standard dosing when using an initial loading dose strategy.21

Dosing algorithms have also been published for paediatric populations. Pharmacogenetic information is not included,3, 6, 22, 23 but paediatric haematologists are interested in updated algorithms including genetic factors.24 In children, the stable dose requirement is related to age, as well as patient height, genetic polymorphisms in VKORC1 and CYP2C9 and indication for warfarin.25, 26, 27 The effect estimates for stable dose vary considerably between publications, both for genetic factors (the estimates of VKORC1, contribution to warfarin stable dose requirements in children varies between 3.7–26.6%, for CYP2C9 0.4–12.8%) and total explained variability (38–72%).25, 26, 27 However, previous studies have not found a relationship between the time spent within the INR range26 and time to therapeutic range27 and either CYP2C9 or VKORC1 polymorphisms. There are data suggesting a relationship between these genetic factors and INR exceeding the target range in the first week of therapy,28 but they have not been replicated, and there is no data on the risk of haemorrhage.

The aims of this study were therefore to examine the association between genetic (VKORC1 and CYP2C9) and non-genetic factors and stable maintenance dosing, and quantify the proportion of variability explained by these factors. We also aimed to examine the association between these genetic polymorphisms and time within therapeutic INR range, an INR above the recommended range in the first week of use, and haemorrhage.

Materials and methods

Study design

This retrospective cohort study received full ethical approval (North West 3 Research Ethics Committee). Participants were recruited between November 2009 and January 2011. Eligibility criteria: warfarin prescribed for 3 months; age 18 years; therapeutic drug monitoring of INR undertaken by Alder Hey Children’s Hospital, UK, a tertiary referral centre; and written informed consent received from parent (participant age <16 years) or participant (if age 16 years). Participant assent was sought from children and young people (each child assessed individually for level of understanding). Refusal of assent by a young person with good understanding of the study was an exclusion criterion.

The majority of children in Alder Hey Children’s hospital on warfarin are cared for in the community, using point-of-care (POC) INR testing. Management of children receiving warfarin using POC testing has been shown to be a safe and effective alternative to testing of INRs in clinic.29 Patients and families inform the cardiac liaison nurse team about the INRs and dose adjustment’s carried out,30 and all this data are recorded electronically. All data (INR, dose, clinical variables) were collected retrospectively from the cardiac liaison team electronic database and medical records, from the date of initiation of warfarin therapy to the date of recruitment. The current recommended levels of anticoagulation for children at Alder Hey children’s hospital are derived from the British Society of Haematology guidelines (Supplementary Table 1).2

Data collection

Warfarin dose and INR values for each POC testing event is routinely collected for all the patients using warfarin at our institution, and these data were extracted onto our study database. From this information, each patient’s full dose and INR history could be determined.

Data were also collected on indication for treatment, target INR, age, gender, height, weight, body mass index, haemorrhagic complications, serial serum albumin concentration(s) (as many children were hypoalbuminaemic at onset of therapy) and height and weight measurements. Clinical data were collected from hospital notes and the cardiac liaison team database.

All variables were checked for completeness and accuracy. Where missing data were noted, an attempt was made to retrieve these data. To check data accuracy, range and consistency checks were undertaken.

DNA collection and extraction and genotyping

Genotyping of CYP2C9*2 (rs 1799853), CYP2C9*3 (rs1057910) and VKORC1-1639 (rs9923231) was undertaken. Full details are given in the online Supplementary Data section.

Outcomes

Study outcomes were as prespecified in the protocol, as follows:

Primary outcome variable

  • The proportion of time in which INR measurements fell within the target range (PTIR) within the first 6 months. Linear interpolation31 was used to estimate the proportion of time patients spent in therapeutic range between two test days.

Secondary outcome measures

  • INR exceeding the target range within the first week of treatment (yes/no);

  • Stable dose (mg per day), defined as the mean daily dose required to achieve three consecutive INR measurements within the individual’s target range over a minimum period of 4 weeks, at the same daily dose;

  • Haemorrhagic complications: classified according to the methods of both Fihn et al. and Streif et al.5, 32

Statistical analysis

All analyses were performed in R version 2.13.33 The following quality control for each single-nucleotide polymorphism (SNP) was undertaken before analyses of association: checks for Hardy–Weinberg equilibrium (P<0.01 indicated deviation); checks for missingness per sample (excluded if >5% missing); checks for missingness per SNP (excluded if >5% missing); checks for SNP minor allele frequency (exclude if minor allele frequency <1%).

For the purpose of calculating the outcome of stable dose, where a patient was on a dosing regimen that required different doses to be taken on different weekdays, the daily warfarin dose was taken as the average dose over a week (for example, if a patient takes 2 mg for two consecutive days and then 3 mg on the third day, the average weekly dose is 16 mg, and therefore the mean daily dose was calculated as 2.3 mg). For the purpose of estimating the INR value for a day that fell between two test days, the method of linear interpolation34 was used.

In terms of tests of association, first, non-genetic variables (age, gender, height, weight, body mass index, albumin, target INR group indication for treatment and haemorrhagic complications), specified a priori as being of potential importance, were each individually tested for association with each outcome. Patients were grouped according to their target INR range, with groups based on the lower limit of the target INR range (rounded to the nearest 0.5).

Two different classifications for indication for treatment were used: two-group, in which patients were divided into non-Fontans and Fontans groups; or three-group, in which patients were divided into non-Fontans cardiac, Fontans cardiac and non-cardiac groups. For the primary outcome and the outcome of INR exceeding target range during the first week, values of these variables at the start of warfarin treatment were referred to. For the outcome of stable dose, values of these variables at the time stability was achieved were referred to. For the outcome of haemorrhagic complications, no tests for association with non-genetic variables were undertaken, as it was not possible to determine what time point should be referred to for obtaining the value of these variables in those not experiencing an event.

For some of the non-genetic variables, there was a considerable amount of missing data (see Tables 1 and 2). In order to minimise the impact of this, multiple imputation using chained equations,34 specifically the predictive mean matching method, was used to impute data for height, weight and albumin at the start of warfarin treatment (all variables had <30% missing observations). Multiple imputation was not used for these variables at the time stable dose was achieved, as the amount of missingness was deemed too high (>40%). Instead, these variables were excluded from the list of potential covariates.

Table 1 Summary of participant characteristics at the start of warfarin therapy and at the time stable dose was achieved
Table 2 P-values from tests of association of non-genetic variables with initial outcome measures

To test for association with each individual SNP, two regression models were fitted. The first (the ‘baseline model’) included all non-genetic factors giving a P-value<0.10 univariately and the second (the ‘genetic model’) was the same as the first but also included covariates to represent the SNP. Both models were compared using the likelihood ratio test. Two analyses were carried out for each SNP: one with no underlying assumptions regarding the mode of inheritance (that is, using two variables to represent the SNP–one representing heterozygotes, one representing mutant homozygotes) and another assuming an additive mode of inheritance (that is, using a single variable to represent the SNP, with heterozyotes coded ‘1’ and mutant homozygotes coded ‘2’). Due to the multiple tests of association, the false discovery rate (FDR) controlling procedure was used, with an overall error rate of 5%.35 For the outcome of haemorrhagic complications and any outcome where none of the non-genetic variables were significant univariately, the baseline model was the null model, as it did not include any variables.

Finally, to investigate the total amount of variation explained by non-genetic and genetic factors combined, a multiple regression model was fitted for each outcome. Covariates included non-genetic factors giving P<0.10 univariately as well as SNPs that were significant under FDR control. For continuous variables, multiple linear regression was performed and the adjusted R2 value was recorded. For binary variables, logistic regression was performed and pseudo R2 values calculated.

Results

Participant characteristics

Participant characteristics are provided in Table 1. A total of 100 patients were recruited (male, n=55), all of whom took warfarin for 6 months. Ethnicity of the patients was reported as European Caucasian (n=97), Black (n=1), Indian (n=1) and Afghan (n=1). Further analyses were restricted to the 97 European Caucasians—85 of these were anticoagulated following surgery for congenital heart disease (Fontan’s procedure n=62; other cardiac procedures n=23) and 12 were non-cardiac patients. The lower limit of the target INR range (rounded to the nearest 0.5) was 1.5 in three patients, 2.0 in 71 patients, 2.5 in eight patients and 3.0 in 15 patients. The genotype frequencies of the patients were: CYP2C9*2 76 (78.4%), 19 (19.6%) and two (2.1%; homozygous wildtype, heterozygote, homozygote variant respectively); CYP2C9*3 79 (81.4%), 18 (18.6%) and 0 (0%); VKORC1-1639 40 (41.2%), 45 (46.4%) and 12 (12.4%). Genotype combinations are shown in Supplementary Table 3. All three SNPs were in Hardy–Weinberg equilibrium (P>0.60).

Outcome data

The mean PTIR in the first 6 months of treatment was 0.50 (s.d. 0.27) and the mean stable warfarin dose was 2.70 (s.d. 1.65) mg per day. Thirty-nine (40.2%) patients had an INR above range in the first week, 49 (50.5%) did not and insufficient data were available to determine this in nine (9.3%) patients. There were no reported major (Streif classification5) or severe (or greater) (Fihn Classification32) haemorrhagic complications. Sixty-nine (71.1%) patients experienced minor (Fihn classification32) or mild (Streif classification5) bleeds. A χ2-analysis between INR4 in week 1 and minor/mild bleeding did not show a significant association (P=0.19).

Analyses of association with each non-genetic variable

Data regarding associations between the non-genetic factors and outcome variables (with the exception of the haemorrhagic complications outcome) are shown in Table 2. It was not possible to test for the association between height, weight, body mass index or albumin levels and stable dose due to the significant amount of missing observations for these variables at the time stable dose was achieved. Target INR group and indication for treatment were both associated with proportion time in INR range during the first 6 months (P<0.10), and were therefore adjusted for in the SNP-association analyses with this outcome. None of the non-genetic variables were associated with the outcome of INR exceeding target range during the first week,whereas age and target INR group were associated with stable dose (P<0.10).

Analyses of association with each SNP

Results from undertaking likelihood ratio tests comparing the baseline model to the genetic model for each outcome are provided in Table 3. As analyses were undertaken both without any assumptions regarding the underlying mode of inheritance and assuming an additive mode, only the lowest P-value is reported. SNPs that remained significant under FDR control were entered into the final multiple regression models (Table 4).

Table 3 Individual SNP association analyses
Table 4 Final multiple regression models

Multiple regression models

The R2 values for multiple regression models built for each outcome, including the non-genetic variables with P<0.10 and genetic variables significant under FDR control, are provided in Table 4.

Together, the indication for treatment and target INR groupings accounted for approximately 11% of the variance in the PTIR during the first 6 months. The presence of the variant allele VKORC1-1639 was associated with a greater time spent within range, with each additional variant allele associated with approximately 13% (95% confidence interval 5–21%) more time spent within the target INR range in the first 6 months. VKORC1-1639 combined with the aforementioned non-genetic factors explained almost 21% variability in proportion of the first 6 months’ treatment time spent within the target INR range. Genetic data related to proportion of time INR within target range is shown in Figure 1.

Figure 1
figure1

Box and whisker plots showing the distribution of PTIR based on (a) target International Normalised Ratio (INR) group, (b) indication treatment group and (c) stratified by vitamin K epoxide reductase complex subunit 1 (VKORC1) genotypes. Boxes represent 25th–75th percentile (interquartile range) of PTIR, whiskers represent 5th–95th percentile and solid lines represent median dose. Open dots denote outliers (a value between 1.5 and 3 times the interquartile range away from the 25th or 75th percentile).

PowerPoint slide

Patients heterozygous for CYP2C9*2 were approximately four times as likely, and mutant homozygotes around 17 times as likely, to have INR values exceeding the target range in the first week as wild-type homozygous patients.

Overall, the patient’s age, target INR range and genotypes at CYP2C9*2 and VKORC1-1639 accounted for approximately 41% of the variability in the warfarin dose required to stabilise INR. The presence of the variant alleles, CYP2C9*2 and VKORC1-1639, was associated with a lower dose required to stabilise INR, with CYP2C9*2 variant alleles associated with an approximate decrease in daily dose of 0.82 mg and VKORC1-1639 variant alleles associated with an approximate decrease of 0.66 mg. On the basis of the change in adjusted R2 values with the addition of the genetic variables, VKORC1-1639 accounted for approximately 7% and CYP2C9*2 approximately 5% of the overall variance in stable dose.

The presence of one variant allele at VKORC1-1639 was associated with an increased likelihood of haemorrhagic complications, with heteroygotes having approximately 4.5 times the likelihood of a bleeding event as wild-type homozygotes. No significant association was found between having two copies of the mutant allele and haemorrhagic complications largely because these individuals were rare and we had insufficient power to detect an association.

Discussion

Many significant pharmacogenomic associations do not make clinical impact due to the lack of replication. We are therefore pleased to report that these data replicate previous publications showing that VKORC1-1639 and CYP2C9*2 both result in decreased stable warfarin dose requirements. The estimates of R2 for daily dose requirement that we have derived for these variant alleles suggests that VKORC1-1639 and CYP2C9*2 contribute 7 and 5%, respectively. Previously published R2 values for the effect of VKORC1-1639 on stable warfarin dose requirements have produced values of 3.7%,27 18.2%26 and 26.6%,25 putting our value of 7% at the lower end of the range. The R2 values previously published for the effects of mutant alleles of CYP2C9 on stable warfarin dose were 0.4%,27 2.026 and 12.8%,25 and again our value of 5% is consistent. The total variability in stable warfarin dosing explained by the genetic factors above, as well as target INR range and age, in our cohort is 41.4%. This is similar to Nowak-Göttl et al. (38%), but lower than Biss et al. (72.4%) and Moreau et al. (69.7%). Possible reasons for the difference include the age of the children studied (younger than in previous studies) and the concomitant use of age as a surrogate for height/weight. Fifty-four percent of our study cohort was less than 6 years old when stable dose was reached, compared with 23% in the cohort studied by Biss et al.25 Similarly, in the study by Moreau et al.26, the mean age was 8.4 years (± 5.6), whereas in this study, it was 6.9 (± 4.5) years. It is possible that genetic factors may become more important as the child grows older and would be consistent with the increased expression of CYP2C9 seen through gestation and childhood.36 An alternative approach would be to conduct a meta-analysis of stable doses of warfarin in children, which was considered by us. However, in the six previously published studies, there was a lack of reporting of key data (including mean dose and s.d. per genotype group). Indeed, the only meta-analysis possible would have been limited to a single polymorphism (VKORC1-1639) and included only two out of the six studies, and so would not have significantly improved the evidence base. Ideally, there is a need for an individual patient data meta-analysis, as well as prospective randomised studies similar to those undertaken in adults.21

The finding that the PTIR is significantly associated with indication for treatment (Fontans or Non-Fontans) also corresponds with that of Moreau et al.26 However, our study showed that PTIR was also significantly associated with VKORC1 polymorphisms, with each additional variant allele associated with approximately 13% more time spent in range in the first 6 months. This contrasts with previous paediatric25 and adult37 studies, where those homozygous for VKORC1 variant alleles spent more treatment time above their INR therapeutic range (although not significantly in the paediatric study25). In addition, Biss et al.28 found no association between the CYP2C9 and VKORC1 genotypes and the proportion of INR values above the target range beyond the first month of therapy.25 This suggests that the adjustment of warfarin doses based on INR after the first month of therapy counteracted the influence of CYP2C9 and VKORC1 genotypes. A possible explanation is that carriers of VKORC1-1639 variant allele are more sensitive to warfarin and may have had more unstable INRs which may have led to more frequent monitoring by their POCT, and more frequent dose titration leading to a more stable INR over the duration of our follow-up. However, we did not have the data to confirm this in our cohort. Nevertheless, it is consistent with the fact that POCT monitoring of INR is associated with safe anticoagulation.38 It may also explain some of the differences between our studies and those which have been published previously–only one of the previous studies26 states that it included children who were monitored by POCT.

Clinically, the initiation of warfarin therapy is a time when large variations in the INR can occur as the stable dose has not yet been established. This replicates the previous data showing that possession of CYP2C9*2 alleles increase the likelihood of above therapeutic range INRs in the first week,28 although as this only explains 6.8% there are clearly other, more significant factors involved here. However, it does add to the evidence suggesting that inclusion of pharmacogenomic data in paediatric dosing algorithms could improve the management of children using warfarin.

This is also the first paediatric study to include minor bleeding complications, as we feel that INR variations are not necessarily associated with poor clinical outcomes. Heterozygotes for VKORC1-1639 were significantly associated with increased minor bleeding complications; however, unlike previous adult studies,39 CYP2C9 variants were not. This may reflect the smaller sample size in our study. We believe these data also add to the clinical case for developing pharmacogenomic-based dosing algorithms for children using warfarin, as it is the first evidence linking the lower dose required in children with VKORC1-1639 mutant alleles with the adverse effects of overtreatment with warfarin.

Although we recruited 100 children, analysis was limited to 97 to ensure identical ethnic origin, and we did not have any children homozygous for CYP2C9*3, limiting the analyses possible with these data. In addition, these data, although recorded systematically from a single site, in a prospective manner, by the team undertaking the POC testing, were collected retrospectively and so there were missing data that could not be determined. It was also not possible to ascertain compliance with medication in this cohort, and this may explain a significant part of the currently unexplained variability. However, this is a closely monitored population through the POC testing system used, and regular education of the patients and family is undertaken, minimising this potential limitation as much as possible.

In conclusion, we have added to the evidence showing that variant alleles in CYP2C9 and VKORC1 are important determinants of warfarin dose requirements and anticoagulation stability in children. However, as with other studies in children, this is based on a retrospective cohort, which may introduce bias into the associations. Our data also indicate that age may be important in determining the relative contribution of genetic and non-genetic factors. Given all of these complexities, the development of dosing algorithms in children will be extremely complicated and will need to initially undertake an individual patient data meta-analysis as was undertaken in adults by the International Warfarin Pharmacogenetics Consortium.40 Furthermore, the dosing algorithms will have to be robust and take into account the pharmacokinetics of warfarin. The importance of dosing algorithms has been highlighted in two recent trials in adults where different results were obtained based on the dosing strategies utilised.21, 41

References

  1. 1

    Monagle P, Michelson AD, Bovill E, Andrew M . Antithrombotic therapy in children. Chest 2001; 119: 344S–370S.

    CAS  Article  PubMed  Google Scholar 

  2. 2

    the British Committee for Standards in Haemotology Baglin TP, Keeling DM, Watson HG . Guidelines on oral anticoagulation: third edition. Br J Haematol 1998; 101: 374–387.

    Article  Google Scholar 

  3. 3

    Andrew M, Marzinotto V, Brooker LA, Adams M, Ginsberg J, Freedom R et al. Oral anticoagulation therapy in pediatric-patients—a prospective-study. Thromb Haemost 1994; 71: 265–269.

    CAS  Article  PubMed  Google Scholar 

  4. 4

    Buck ML . Anticoagulation with warfarin in infants and children. Ann Pharmacother 1996; 30: 1316–1322.

    CAS  Article  PubMed  Google Scholar 

  5. 5

    Streif W, Andrew M, Marzinotto V, Massicotte P, Chan AKC, Julian JA et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood 1999; 94: 3007–3014.

    CAS  PubMed  Google Scholar 

  6. 6

    Bonduel M, Sciuccati G, Hepner M, Torres AF, Pieroni G, Frontroth JP et al. Acenocoumarol therapy in pediatric patients. J Thromb Haemost 2003; 1: 1740–1743.

    CAS  Article  PubMed  Google Scholar 

  7. 7

    Tait RC, Ladusans EJ, ElMetaal M, Patel RG, Will AM . Oral anticoagulation in paediatric patients: dose requirements and complications. Arch Dis Child 1996; 74: 228–231.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. 8

    Wadelius M, Pirmohamed M . Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007; 7: 99–111.

    CAS  Article  PubMed  Google Scholar 

  9. 9

    Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MTM et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753–764.

    CAS  Article  PubMed  Google Scholar 

  10. 10

    Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329–2333.

    CAS  Article  PubMed  Google Scholar 

  11. 11

    Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D . Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 2009; 113: 3925–3930.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. 12

    Limdi N, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 2008; 83: 312–321.

    CAS  Article  PubMed  Google Scholar 

  13. 13

    Limdi NA, Karnett D, Goldstein JA, Beasley TM, McGwin G, Adler BK et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 2008; 9: 511–526.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. 14

    Obayashi K, Nakamura K, Kawana J, Ogata H, Hanada K, Kurabayashi M et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther 2006; 80: 169–178.

    CAS  Article  PubMed  Google Scholar 

  15. 15

    Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285–2293.

    CAS  Article  PubMed  Google Scholar 

  16. 16

    Veenstra DL, You JHS, Rieder MJ, Farin FM, Wilkerson HW, Blough DK et al. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 2005; 15: 687–691.

    CAS  Article  PubMed  Google Scholar 

  17. 17

    Cavallari LH, Momary KM, Patel SR, Shapiro NL, Nutescu E, Viana MAG . Pharmacogenomics of warfarin dose requirements in Hispanics. Blood Cells Mol Dis 2011; 46: 147–150.

    CAS  Article  PubMed  Google Scholar 

  18. 18

    Jorgensen AL, Al-Zubiedi S, Zhang JE, Keniry A, Hanson A, Hughes DA et al. Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics 2009; 19: 800–812.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. 19

    Tan G-M, Wu E, Lam Y-Y, Yan BP . Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics 2010; 11: 439–448.

    CAS  Article  PubMed  Google Scholar 

  20. 20

    You JHS, Wong RSM, Waye MMY, Mu YW, Lim CK, Choi KC et al. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. J Thromb Thrombolysis 2011; 31: 113–118.

    CAS  Article  PubMed  Google Scholar 

  21. 21

    Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013; 369: 2294–2303.

    CAS  Article  PubMed  Google Scholar 

  22. 22

    Manco-Johnson MJ . How I treat venous thrombosis in children. Blood 2006; 107: 21–29.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. 23

    Payne JH . Aspects of anticoagulation in children. Br J Haematol 2010; 150: 259–277.

    CAS  Article  PubMed  Google Scholar 

  24. 24

    Thornburg CD, Jones E, Bomgaars L, Gage BF . Pediatric warfarin practice and pharmacogenetic testing. Thromb Res 2010; 126: E144–E146.

    CAS  Article  PubMed  Google Scholar 

  25. 25

    Biss TT, Avery PJ, Brandao LR, Chalmers EA, Williams MD, Grainger JD et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood 2012; 119: 868–873.

    CAS  Article  PubMed  Google Scholar 

  26. 26

    Moreau C, Bajolle F, Siguret V, Lasne D, Golmard JL, Elie C et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood 2012; 119: 861–867.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  27. 27

    Nowak-Gottl U, Dietrich K, Schaffranek D, Eldin NS, Yasui Y, Geisen C et al. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood 2010; 116: 6101–6105.

    Article  PubMed  Google Scholar 

  28. 28

    Biss TT, Avery PJ, Williams MD, BrandÃO LR, Grainger JD, Kamali F . The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children. J Thromb Haemost 2013; 11: 373–375.

    CAS  Article  PubMed  Google Scholar 

  29. 29

    Bradbury MJE, Taylor G, Short P, Williams MD . A comparative study of anticoagulant control in patients on long-term warfarin using home and hospital monitoring of the international normalised ratio. Arch Dis Child 2008; 93: 303–306.

    CAS  Article  PubMed  Google Scholar 

  30. 30

    Murray M, Keenan R, Billington R . Standard Operating Procedure (SOP) for the Management of Children on Warfarin at a Paediatric Regional Anticoagulation Centre. Alder Hey Children’s Hospital: Liverpool, 2005.

    Google Scholar 

  31. 31

    Rosendaal FR, Cannegieter SC, Van der Meer FJM, Briet E . A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236–239.

    CAS  Article  PubMed  Google Scholar 

  32. 32

    Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH . The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996; 124: 970–979.

    CAS  Article  PubMed  Google Scholar 

  33. 33

    R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria, 2011.

  34. 34

    van Buuren S, Groothuis-Oudshoorn K . mice: Multivariate Imputation by Chained Equations in R. J Stat Softw 45: 1–67.

  35. 35

    Benjamini Y, Hochberg Y . Controlling the false discovery rate—a practical and powerful approach to multiple testing. J R Statist Soc B 1995; 57: 289–300.

    Google Scholar 

  36. 36

    Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004; 308: 965–974.

    CAS  Article  PubMed  Google Scholar 

  37. 37

    Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999–1008.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  38. 38

    Heneghan C, Ward A, Perera R, Bankhead C, Fuller A, Stevens R et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 379: 322–334.

  39. 39

    Sanderson S, Emery J, Higgins J . CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet[trade] systematic review and meta-analysis. Genet Med 2005; 7: 97–104.

    CAS  Article  PubMed  Google Scholar 

  40. 40

    Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR . Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One 2012; 7: e44064.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  41. 41

    Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013; 369: 2283–2293.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was funded by the MRC Centre for Drug Safety Science (CDSS) at the University of Liverpool and the Department of Health Chair in Pharmacogenetics.

Author information

Affiliations

Authors

Corresponding author

Correspondence to M Pirmohamed.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website

Supplementary information

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hawcutt, D., Ghani, A., Sutton, L. et al. Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. Pharmacogenomics J 14, 542–548 (2014). https://doi.org/10.1038/tpj.2014.31

Download citation

Further reading

Search

Quick links